Acute Respiratory Distress Syndrome (ARDS) Market CAGR Forecast Through 2030: Key Trends Shaping Industry Expansion
Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.
Acute Respiratory Distress Syndrome (ARDS) Market Size Forecast: How Big Could The Market Get By 2030?
The market size for acute respiratory distress syndrome (ards) has experienced rapid growth in recent years. It is projected to expand from $1.41 billion in 2025 to $1.56 billion in 2026, reflecting a compound annual growth rate (CAGR) of 10.5%. This historical growth can be attributed to several factors including a rising incidence of respiratory infections, the expansion of hospital ICU infrastructure, increased awareness regarding ARDS management protocols, the limited availability of advanced ventilation devices, and the adoption of supportive care practices.
The market size for acute respiratory distress syndrome (ARDS) is anticipated to experience rapid expansion in the coming years. It is projected to grow to $2.42 billion in 2030, achieving a compound annual growth rate (CAGR) of 11.7%. The expected growth during this period can be attributed to technological advancements in mechanical ventilation and ECMO systems, increasing research and development in ARDS therapeutics, a global expansion of critical care units, rising investment in personalized patient management solutions, and the growing prevalence of severe pneumonia and sepsis. Major trends observed in the forecast period include the rising adoption of mechanical ventilation and ECMO devices, an increasing prevalence of ARDS due to COVID-19 and other respiratory diseases, the growing use of advanced diagnostic tests for early detection, the expansion of critical care and ICU facilities, and a focus on personalized and supportive care management.
Get A Free Sample Report With In-Depth Market Insights:
Acute Respiratory Distress Syndrome (ARDS) Market Growth Momentum: What Factors Are Shaping Demand?
An escalating number of respiratory illnesses is expected to drive the expansion of the acute respiratory distress syndrome (ARDS) market moving forward. Respiratory illness refers to a variety of medical conditions that impact the respiratory system, including airways and lungs, often leading to breathing difficulties. The rising incidence of respiratory illnesses, such as COVID-19, stands as a key factor propelling the growth of the acute respiratory distress syndrome (ARDS) market. As more individuals contract respiratory ailments, the demand for ARDS treatments and therapies is anticipated to increase, stimulating market growth. For instance, in October 2024, the National Asthma Council, an Australia-based non-profit organization, reported that in 2023, Australia registered a total of 474 asthma-related deaths, comprising 325 females and 149 males. This figure closely resembles the 473 asthma-related deaths recorded in 2022, demonstrating a consistent pattern in asthma mortality over these two years. Consequently, the increasing occurrence of respiratory illnesses is a significant driver for the growth of the acute respiratory distress syndrome (ARDS) market.
Acute Respiratory Distress Syndrome (ARDS) Market Segmentation And Category Overview
The acute respiratory distress syndrome (ards) market covered in this report is segmented –
1) By Type: Diagnosis, Treatment
2) By Cause: COVID-19 Disease 2019 (COVID-19), Sepsis, Inhalation Of Harmful Substances, Severe Pneumonia, Other Causes
3) By Severity: Mild, Moderate, Severe
4) By End User: Hospitals, Clinics, Ambulatory Service Centers, Other End Users
Subsegments:
1) By Diagnosis: Imaging Tests, Blood Tests
2) By Treatment: Mechanical Ventilation, Medications, Extracorporeal Membrane Oxygenation (ECMO), Supportive Care
Acute Respiratory Distress Syndrome (ARDS) Market Trends Redefining Industry Growth
Companies operating within the acute respiratory distress syndrome market are increasingly concentrating on the creation of sophisticated immune modulators to improve patient survival rates and lessen inflammation. Immune modulators function by re-establishing immune balance, specifically targeting impaired inflammatory pathways without suppressing overall immune function. For instance, in June 2025, BioAegis Therapeutics, a US-based clinical-stage firm, secured FDA Fast Track designation for its primary candidate, recombinant human plasma gelsolin (rhu-pGSN), intended for the treatment of ARDS. This therapy operates by restoring gelsolin, which is a vital immune regulatory protein, to control NLRP3 inflammasome activation, boost microbial clearance, eliminate toxic actin and inflammatory mediators, and regulate macrophage activity. rhu-pGSN is currently undergoing evaluation in a 600-patient global Phase 2b trial for moderate to severe ARDS and could potentially become accessible through the FDA Expanded Access or Compassionate Use program. The Fast Track designation facilitates quicker regulatory engagements, continuous review of marketing submissions, and eligibility for priority review, which could hasten its market introduction and provide a new therapeutic option for patients with limited choices.
Acute Respiratory Distress Syndrome (ARDS) Market Competitive Analysis Of Leading Industry Participants
Major companies operating in the acute respiratory distress syndrome (ards) market are Johnson & Johnson Services Inc., Novartis AG, GlaxoSmithKline plc, Medtronic plc, Boehringer Ingelheim International GmbH, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Koninklijke Philips N.V., Baxter International Inc., Teva Pharmaceutical Industries Ltd., CSL Behring, Terumo Corporation, Smiths Medical Inc., Dräger Safety AG & Co. KGaA, Getinge AB, Mallinckrodt plc, Masimo Corporation, Fisher & Paykel Healthcare Corporation Limited, Hamilton Medical AG, Windtree Therapeutics Inc., Faron Pharmaceuticals Oy
View The Full Acute Respiratory Distress Syndrome (ARDS) Market Report:
Acute Respiratory Distress Syndrome (ARDS) Market Regional Split: Which Areas Are Fueling Growth?
North America was the largest region in the acute respiratory distress syndrome (ARDS) market in 2025. The regions covered in the acute respiratory distress syndrome (ards) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Reach Out To Our Team:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
